Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Vulvar Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
0 drugs · 0 active trials
no drug at this stage
0 drugs · 0 active trials
no drug at this stage
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cisplatin | Phase 3 | Phase 3 | 3 | 2 | 1 | 7 | 0 | — | — | 2001-03 |
| Nivolumab | Phase 2 | Phase 2 | 4 | 0 | 0 | 5 | 0 | — | — | Jan 30, 2017 |
| Pembrolizumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Dec 18, 2015 |
| Bevacizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | 2007-05 |
| Paclitaxel | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | 2001-02 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Mar 7, 2023 |
| Atezolizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Mar 3, 2017 |
| Bleomycin | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Apr 8, 2022 |
| Gemcitabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2012-05 |
| Carboplatin | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2012-05 |
| Imiquimod | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2007-04 |
| Ipilimumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jan 30, 2017 |
| Avelumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 1, 2017 |
| Belzutifan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 20, 2024 |
| Cabozantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 11, 2022 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 1, 2025 |
| Cyclophosphamide | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2024-10 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 22, 2024 |
| Doxorubicin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 22, 2024 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2024-10 |
| Lenvatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 24, 2025 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 27, 2017 |
| Tisotumab Vedotin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-11 |
| Tivozanib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 7, 2021 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jun 1, 2018 |
| Fluorouracil | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 29, 2017 |
| Niraparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 29, 2017 |
| Tremelimumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 1, 2018 |
| Docetaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-03 |
| Topotecan | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-02 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.